Home / Business / Healthcare & Pharmaceutical Tools: Save | Print | E-mail | Most Read | Comment
Guilin Sanjin's H1 net profit up 13.34%
Adjust font size:

Guilin Sanjin Pharmaceutical Co, a traditional Chinese medicine maker, saw strong earnings this year, according to its interim report, which the company released yesterday.

Guilin Sanjin, the first company to raise money from Shenzhen Stock Exchange market via an initial public offering (IPO) after the ban on new share issues was lifted last month, posted a net profit of about 159.98 million yuan ($23.42 million) in the first half, up 13.34 percent year-on-year.

The company reaped a revenue of 479.85 million yuan, up nine percent over the same period a year earlier.

In the first six months this year, the company's per-share earnings rose 11.43 percent to 0.39 yuan and its return on equity ratio reached 20.86 percent, up 4.48 percent year-on-year.

(Chinadaily.com.cn July 29, 2009)

Tools: Save | Print | E-mail | Most Read Bookmark and Share
Pet Name
China Archives
Related >>
- Investors flock to buy Guilin Sanjin shares
- Guilin Sanjin says IPO price fixed at 19.8 yuan per share
- Guilin Sanjin sets the China IPO ball rolling
June 7 Tokyo 2nd China-Japan High-Level Economic Dialogu

June 30 Shanghai 2009 Automotive Engine Technology Seminar

September 8-12 Xiamen China Int'l Fair for Investment and Trade
- Output of Major Industrial Products
- Investment by Various Sectors
- Foreign Direct Investment by Country or Region
- National Price Index
- Value of Major Commodity Import
- Money Supply
- Exchange Rate and Foreign Exchange Reserve
- What does the China-Pakistan Free Trade Agreement cover?
- How to Set up a Foreign Capital Enterprise in China?
- How Does the VAT Works in China?
- How Much RMB or Foreign Currency Can Be Physically Carried Out of or Into China?
- What Is the Electrical Fitting in China?